Member Info for PhatStyle4321

Very positive News and what's especially pleasing is the cash position OXP are well funded and more to do all what they have set out to do, therefore any more progression news will see this quickly back to 7p

End of next week, prediction 6.25p, if any news is released then triple that price GLA

https://www.google.co.uk/amp/www.independent.co.uk/life-style/health-and-families/health-news/statins-cancer-death-rates-cure-reduction-research-statistics-a7127711.html%3famp?client=safari# Great news this is, would be nice if OXP initiated the launch of the statin research as recently a lot of media attention on this has come about. Also nice recovery of the share price this week, can see it going back to 7p easily.

News should be on the way soon, every week further is one week closer, the deal is round the corner and currently in negotiations, Brexit effects are starting to disappear, in 3 months time we will be above double figures 15p plus on news

Nothing in the fundamentals has changed, Brexit has maybe spooked a few people, but the products haven't changed and I can guarantee their will be a partner by the end of this year, the drugs are the future, they do the same thing without any side effects. The share price at the moment is a steal and in the next few months will be back to 7p, if I had the money I would be topping up

It's been over 5 months since OXP has initiated conversations with the big pharmas, however I think the cloud of the EU refendum has put a hold on things such as this, therefore if any deal is done, news will be released after the vote next week. Once there is positive news this is going to rocket substantially

News could be out anytime, a JV would set this stock a light I would be looking at 20 plus on news, the revenue stream would be immense

http://www.dailymail.co.uk/health/article-2042132/How-taking-painkillers-destroy-stomach-lining-days.html

Could be anytime soon we get an update on potential partnering, it's excited to see who will we get or in fact who we will choose. GLA

The RNS released on the 25/01 states explicitly that OXP are entering partner discussions Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Ready to enter partnering discussions on key OXPzeroTM NSAIDs Oxford Pharmascience, the Company that redevelops medicines to make them better, safer and easier to take, today announces that it has finalised commercial materials to allow the Company to enter partnering discussions for both its OXPzeroTM Ibuprofen and OXPzeroTM Naproxen assets. The Company reported in November 2015 that it was in the final stages of completing preparation of these commercial discussion materials for the OXPzeroTM Ibuprofen platform. This task has now been completed and, with further technical progress made in recent months across the wider platform, the Board is now pursuing opportunities for commercialisation of both its lead OXPzeroTM Ibuprofen asset and OXPzeroTM Naproxen. Ibuprofen and naproxen are the two dominant NSAID molecules in the pain relief and anti-inflammatory sector, with combined worldwide sales in excess of $5bn per annum.(1) OXPzeroTM NSAIDs have been demonstrated to deliver a range of key benefits that offer competitive advantage and meaningful differentiation. Specifically, by comparison with generic oral tablets, OXPzeroTM NSAIDs: - are milder in the gastrointestinal (GI) tract, delivering major reduction in GI mucosal damage; - completely mask the bitter taste/burn associated with NSAIDs; and - deliver an attractive PK profile with adaptable drug release properties. These characteristics enable multiple advantaged product applications across over-the-counter, pharmacist-only sales and prescription markets. The Company has identified major opportunities in: - Pain: OXP believes that the GI mildness of the OXPzeroTM products can be capitalised on in order to address the needs of patients exposed to higher risk of GI damage. For example, OXPzeroTM NSAIDs can be widely used in pain management for the over-60s as well as the treatment of chronic or severe pain in other age groups, with reduced GI risks; - Cough and Cold: Ibuprofen has inherent advantages in efficacy and duration of effect versus paracetamol, however paracetamol dominates non-tablet forms of cough and cold remedies because of its GI mildness and taste advantages. OXPzeroTM NSAID products enable superior, longer lasting, non-tablet forms versus paracetamol without the inferior GI profile or taste issues associated with standard ibuprofen; and - Easy-to-take, non-tablet products: formulations of OXPzeroTM products lend themselves to being taken 'on the move'. For example, the technology allows for high dose (200mg/5ml) suspension formulations which are not currently available due to the bitter taste/burn of Ibuprofen at that dose level. As previously announced, the Company initiated contact in 2015 with a number of large, glo

Ok after reading some of your posts I thought I needed to reply in a timely fashion. First of all I am very passionate about OXP and what they do they are truly one of a kind and I am confident they will pull this off. In my experience as a business man, and having worked in this sector any partnering discussions in my experience would always have a deadline and it's usually is between 4-6 months, therefore when we received our RNS on the 25/01 it leaves us straight in that time slot Any kind of offer has to have a deadline, those deadline can be extended depending on the process of due diligence. If I was to think like the CEO of a big pharma this product would be a great way to get the edge over its competitors, I don't pretend to know any inside info because otherwise I would be a multi millionaire. ciao for now

Deadline for the big pharma companies to make an offer is approaching so should be expecting a RNS this week or next. Any kind of RNS indicating interest or a realised offer will send this share straight to 25p plus

After speaking with the owners at the presentation, we should be expecting an offer within the next few weeks, they were very encouraged by the big companies and frankly this is too much an opportunity to pass, especially as their competitors will have an edge over them, 30p target in the few weeks

A lot of people I spoke to fell in love with the concept and were looking to buy today should see a lift off today, should expect over 8p by weeks end

That's where I see it going today over 8p would be magnificent

Could be some huge buys after tomorrow's presentation also there might be some interesting news

It looks like someone's loading big on these shares, another institution maybe ready for the takeover bid of a big pharma that wants a range of OXP products

Should be coming in the next few weeks and when it does 25p will be history, 50pnis definitely a realistic target

I think that we are going to see a significant rally especially after this presentation for Oxford, the story is probably one of the best I've heard in a long time and I've been doing this for many years, I am confident that in order for us to develop as a human race, products such as those Oxford are developing need to be brought to market, they are a lot more efficient and reduction in cost for the global health service will be huge. Next target is 25p and that could be reached in a matter of week, only 33% of shares in free float.

Trade that occurred yesterday £100,000 BUY at 8p, looks like something is happening very soon, news must have leaked and there is now a JV happy days, no one is investing £100,000 unless they are confident something is going on